

Japan's Yakult transfers marketing authorisation of cancer drug Elplat to Takata

27 October 2023 | News

Elplat is an anticancer platinum drug, for which Yakult Honsha acquired development and commercialisation rights in Japan from Debiopharm

Debiopharm International SA, Yakult Honsha and Takata Pharmaceutical have agreed that Yakult Honsha will transfer the marketing authorisation in Japan of anticancer drug Elplat (generic name: oxaliplatin, trade name: Elplat I.V. Infusion Solution 50 mg, 100 mg, 200 mg) that Yakult Honsha licensed from Debiopharm and that was manufactured and marketed in Japan, to Takata Pharmaceutical in phases.

To achieve a smooth transfer of the marketing authorisation of Elplat as well as stable supply and drug information activities of Elplat to Takata Pharmaceutical, the transfer will be performed in 2- phased plan consisting of the transfer of sales and distribution activities and subsequent transfer of the marketing authorisation.

Transfer of sales and distribution will be completed by April 2024 (tentative), while transfer of the marketing authorisation is to be done by April 2025 (tentative).

Elplat is an anticancer platinum drug, for which Yakult Honsha acquired development and commercialization rights in Japan from Swiss firm Debiopharm in 1997. Elplat was approved for the indication for the treatment of curatively unresectable advanced/recurrent colorectal cancer in March 2005, and launched on the market in April of the same year. In August 2009, Elplat became indicated for postoperative adjuvant chemotherapy for colon cancer.